Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Berchuck, A, Cirisano, F, Lancaster, JM, Schildkraut, JM, Wiseman, RW, Futreal, A, and Marks, JR. "Role of BRCA1 mutation screening in the management of familial ovarian cancer." Am J Obstet Gynecol 175, no. 3 Pt 1 (September 1996): 738-746. (Review)

Scholars@Duke

Terry, LA, Boyd, J, Alcorta, D, Lyon, T, Solomon, G, Hannon, G, Berchuck, A, Beach, D, and Barrett, JC. "Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines." Mol Carcinog 16, no. 4 (August 1996): 221-228.

Full Text

Vaughn, JP, Davis, PL, Jarboe, MD, Huper, G, Evans, AC, Wiseman, RW, Berchuck, A, Iglehart, JD, Futreal, PA, and Marks, JR. "BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells." Cell Growth Differ 7, no. 6 (June 1996): 711-715.

Scholars@Duke

Lancaster, JM, Wooster, R, Mangion, J, Phelan, CM, Cochran, C, Gumbs, C, Seal, S, Barfoot, R, Collins, N, Bignell, G, Patel, S, Hamoudi, R, Larsson, C, Wiseman, RW, Berchuck, A, Iglehart, JD, Marks, JR, Ashworth, A, Stratton, MR, and Futreal, PA. "BRCA2 mutations in primary breast and ovarian cancers." Nature Genetics 13, no. 2 (June 1996): 238-240.

Full Text

Lancaster, JM, Cochran, CJ, Brownlee, HA, Evans, AC, Berchuck, A, Futreal, PA, and Wiseman, RW. "Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test." J Natl Cancer Inst 88, no. 8 (April 17, 1996): 552-554.

Scholars@Duke

Olt, G, Soper, J, Ramakrishnan, S, Xu, F, Berchuck, A, Clarke-Pearson, D, Dodge, R, and Bast, RC. "Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer." American Journal of Obstetrics and Gynecology 174, no. 4 (April 1996): 1316-1319.

Full Text

"Early ovarian cancer: A review of its genetic and biologic factors, detection, and treatment." Current Problems in Cancer 20, no. 2 (March 1996): 86-137.

Full Text

Boente, MP, Hamilton, TC, Godwin, AK, Buetow, K, Kohler, MF, Hogan, WM, Berchuck, A, and Young, RC. "Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment." Curr Probl Cancer 20, no. 2 (March 1996): 83-137. (Review)

Scholars@Duke

Lancaster, JM, Wiseman, RW, and Berchuck, A. "An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene." Obstetrics and Gynecology 87, no. 2 (February 1996): 306-309.

Full Text

Hussein, AM, Petros, WP, Ross, M, Vredenburgh, JJ, Affrontil, ML, Jones, RB, Shpall, EJ, Rubin, P, Elkordy, M, Gilbert, C, Gupton, C, Egorin, MJ, Soper, J, Berchuck, A, Clarke-Person, D, Berry, DA, and Peters, WP. "A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies." Cancer Chemother Pharmacol 37, no. 6 (1996): 561-568.

Scholars@Duke

Pages